[Betaleukin (human recombinant interleukin-1beta) for the prevention and correction of toxic leukopenia in chemotherapy of malignant neoplasms].
The marked and quick response to betaleukin, a preparation of recombinant human interleukin-1 beta, was demonstrated in 77 cases of extensive solid neoplasms and non-Hodgkin's disease, suffering combination chemotherapy-induced toxic leukopenia. Leukopoiesis was effectively stimulated by intravenous administration, of 10-20 ng/kg weight, dropwise for 5 days. Due to adjuvant betaleukin in identical dosage, chemotherapy was continued, in moderate leukopenia, without causing leukocyte count to drop. The untoward side-effects (chiefly. hyperthermia including fever) were reversible and did not hamper treatment.
Gershanovich
M L
ML
Prof. N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Filatova
L V
LV
Ketlinskiĭ
S A
SA
Simbirtsev
A S
AS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D006397:Hematinics; D007375:Interleukin-1; D011994:Recombinant Proteins
Betaleĭkin (rekombinantnyĭ interleĭkin-1beta cheloveka) v profilaktike i korrektsii toksicheskoĭ leĭkopenii pri kombinirovannoĭ khimioterapii zlokachestvennykh opukholeĭ.